This new approach to genomic data will provide new insights to individuals for diseases such as cancers, epilepsy, diabetes, Alzheimer's, Parkinson's disease and other rare diseases. People in all countries will be able to benefit from Dante Labs AI.

Dante Labs introduced 30x long reads whole genome sequencing based on Oxford Nanopore technology. This is the first long reads whole genome available commercially worldwide. Sequencing will be performed at Dante Labs' new highly automated, certified third-generation sequencing center in L'Aquila, Italy.

Dante Labs takes the first step of its ambitious project to integrate high coverage genome sequencing in clinical care in clinics and hospitals.